132 related articles for article (PubMed ID: 36939482)
1. Prospective Assessment of Otologic Adverse Events due to Teprotumumab: Preliminary Results.
Kay-Rivest E; Belinsky I; Kozlova A; Byrd E; McMenomey SO; Jethanamest D
Otolaryngol Head Neck Surg; 2023 May; 168(5):1164-1169. PubMed ID: 36939482
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
3. Frequency and Patterns of Hearing Dysfunction in Patients Treated with Teprotumumab.
Keen JA; Correa T; Pham C; Claussen AD; Hansen MR; Carter KD; Shriver EM
Ophthalmology; 2024 Jan; 131(1):30-36. PubMed ID: 37567417
[TBL] [Abstract][Full Text] [Related]
4. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
Sears CM; Azad AD; Amarikwa L; Pham BH; Men CJ; Kaplan DN; Liu J; Hoffman AR; Swanson A; Alyono J; Lee JY; Dosiou C; Kossler AL
Am J Ophthalmol; 2022 Aug; 240():1-13. PubMed ID: 35227694
[TBL] [Abstract][Full Text] [Related]
5. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
6. [Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia].
Lisowska G; Namysłowski G; Hajduk A; Polok A; Tomaszewska R; Misiołek M
Otolaryngol Pol; 2006; 60(3):415-20. PubMed ID: 16989457
[TBL] [Abstract][Full Text] [Related]
7. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
Knight KR; Kraemer DF; Winter C; Neuwelt EA
J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
[TBL] [Abstract][Full Text] [Related]
8. Distortion-product otoacoustic emission test performance for ototoxicity monitoring.
Reavis KM; McMillan G; Austin D; Gallun F; Fausti SA; Gordon JS; Helt WJ; Konrad-Martin D
Ear Hear; 2011 Feb; 32(1):61-74. PubMed ID: 20625302
[TBL] [Abstract][Full Text] [Related]
9. [Effect of inner ear hearing loss on delayed otoacoustic emissions (TEOAE) and distortion products (DPOAE)].
Hoth S
Laryngorhinootologie; 1996 Dec; 75(12):709-18. PubMed ID: 9081275
[TBL] [Abstract][Full Text] [Related]
10. The Ototoxic Potential of Cobalt From Metal-on-Metal Hip Implants: Objective Auditory and Vestibular Outcome.
Leyssens L; Vinck B; Van Der Straeten C; De Smet K; Dhooge I; Wuyts FL; Keppler H; Degeest S; Valette R; Lim R; Maes L
Ear Hear; 2020; 41(1):217-230. PubMed ID: 31169566
[TBL] [Abstract][Full Text] [Related]
11. Application of distortion product otoacoustic emissions to inflation of the eustachian tube in low frequency tinnitus with normal hearing.
Wang H; Song N; Li X; Lv H
Auris Nasus Larynx; 2013 Jun; 40(3):273-6. PubMed ID: 23103152
[TBL] [Abstract][Full Text] [Related]
12. Distortion-product otoacoustic emissions and cochlear microphonics: relationships in patients with and without endolymphatic hydrops.
Fetterman BL
Laryngoscope; 2001 Jun; 111(6):946-54. PubMed ID: 11404602
[TBL] [Abstract][Full Text] [Related]
13. Ultra-High Frequency Distortion Product Otoacoustic Emissions for Detection of Hearing Loss and Tinnitus.
Jedrzejczak WW; Pilka E; Ganc M; Kochanek K; Skarzynski H
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206311
[TBL] [Abstract][Full Text] [Related]
14. Ototoxicity screening of patients treated with streptomycin using distortion product otoacoustic emissions.
Md Daud MK; Mohamadl H; Haron A; Rahman NA
B-ENT; 2014; 10(1):53-8. PubMed ID: 24765829
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the possible effect of magnetic resonance imaging noise on peripheral hearing organ with the otoacoustic emission.
Turay CB; Ozer F; Yildirim T; Erbek S
Am J Otolaryngol; 2020; 41(6):102586. PubMed ID: 32629148
[TBL] [Abstract][Full Text] [Related]
16. Effect of cisplatin chemotherapy on the inner ear function and serum prestin concentration.
Jalali MM; Saedi HS; Saadat F
Eur Arch Otorhinolaryngol; 2022 Jun; 279(6):2783-2789. PubMed ID: 34213608
[TBL] [Abstract][Full Text] [Related]
17. Test-retest reliability of distortion-product thresholds compared to behavioral auditory thresholds.
Bader K; Dierkes L; Braun LH; Gummer AW; Dalhoff E; Zelle D
Hear Res; 2021 Jul; 406():108232. PubMed ID: 33984603
[TBL] [Abstract][Full Text] [Related]
18. Ototoxicity and Teprotumumab.
Highland J; Gordon S; Reddy D; Patel N
Ann Otol Rhinol Laryngol; 2022 Aug; 131(8):910-913. PubMed ID: 34448414
[TBL] [Abstract][Full Text] [Related]
19. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.
Al-Malky G; Dawson SJ; Sirimanna T; Bagkeris E; Suri R
J Cyst Fibros; 2015 Mar; 14(2):248-54. PubMed ID: 25127922
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
